PRESS RELEASE
News
-
-
PRESS RELEASE
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
UCB presents positive results from GEMZ phase 3 study at AES showing significant reduction in countable motor seizure frequency in CDKL5 Deficiency Disorder. Study demonstrates efficacy and safety of fenfluramine as adjunctive treatment -
PRESS RELEASE
Eight years of research and development – proprietary algorithms enable the strategic scaling of trading capacities
Alphawave GmbH concludes an 8-year R&D phase, introducing scalable trading capacities. Proprietary algorithms drive strategic trading. Impressive internal trading results shared -
-
PRESS RELEASE
Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform
Xlife Sciences AG announces strategic exit of 12 projects to Grupo Landsteiner, forming a transcontinental life sciences platform with a NASDAQ listing in 2026 -
-
-
-
PRESS RELEASE
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026 -
PRESS RELEASE
Family Support Now Make-or-Break for Overseas Postings, New Study Reveals
New research from AXA Global Healthcare reveals the importance of family support for international assignees, urging employers to adopt a more holistic approach. The 2025 World of Work Report emphasizes the impact on assignees' wellbeing and success criteria on global placements
